JANX — Janux Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1817713 ·
Last close
$10.71
Market Cap
$655.27M
52W High
$35.34
52W Low
$10.50
ADV30
995,683
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 9,289,000 | — | -31,258,000 | -21,570,000 | 983,655,000 | 41,818,000 | 72,043,000 |
| Jun 2026 | 10,267,000 | — | -31,690,000 | -21,972,000 | 1,007,653,000 | 27,768,000 | 79,669,000 |
| Mar 2026 | 3,733,000 | — | -34,213,000 | -24,361,000 | 1,028,225,000 | 51,828,000 | 86,690,000 |
| Dec 2025 | 0 | — | -42,401,000 | -31,946,000 | 1,001,565,000 | 52,334,000 | 44,743,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,251,000
Investing CF
$7,351,000
Financing CF
$9,222,000
CapEx
$-674,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.64
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-397,715,000
Inventory
—
Receivables
$6,325,000
ST Investments
$943,145,000
EBIT TTM
$-143,555,000
Pretax Income TTM
$-102,592,000
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$23,289,000
EBITDA
$-137,704,000
Free Cash Flow
$-24,240,250
Enterprise Value
$153,326,640
Total Cash
$945,716,992
Total Debt
$20,380,000
Shares Out
61,183,417
Trailing EPS
$-1.59
Book Value
$14.90
ROE
-10.6%
ROA
-8.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -157,667,000 | -113,625,000 | 1,001,565,000 | 44,743,000 | 956,822,000 | -82,235,000 |
| Dec 2024 | 10,588,000 | -98,847,000 | -68,994,000 | 1,061,516,000 | 38,735,000 | 1,022,781,000 | -43,814,000 |
| Dec 2023 | 8,083,000 | -72,979,000 | -58,293,000 | 380,407,000 | 36,058,000 | 344,349,000 | -50,575,000 |
| Dec 2022 | 8,612,000 | -67,091,000 | -63,059,000 | 364,010,000 | 43,270,000 | 320,740,000 | -42,922,000 |
TTM Snapshot
Revenues TTM
$24,000,000
NetIncome TTM
$-102,592,000
OpCashFlow TTM
—
Assets (Latest)
$1,007,653,000
Forward EPS
$-2.56
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $10.31 · call volume: 280 · put volume: 947
Expected Move to 2027-01-15:
±$8.90
(86.32%) —
implied range
$1.41 –
$19.21
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | $660.27M | $19.20 | — |
| ANNX | Annexon, Inc. | $661.95M | $3.47 | — |
| GERN | GERON CORP | $644.24M | $1.00 | — |
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
News headlines (Yahoo Finance, 1h cache)
Janux Therapeutics Stock In Focus As Loss Narrows And Phase 1 Data Nears
2026-11-10 01:16 · Yahoo
Janux Reports Deep B-Cell Depletion in Initial Phase 1 Trial of JANX011; Shares Fall
2026-11-09 15:52 · Yahoo
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
2026-11-09 13:30 · Yahoo
Janux Therapeutics (JANX) Earnings Beat Brings Its Pricey Valuation Back Into Focus
2026-11-07 14:09 · Yahoo
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 21:10 · Yahoo
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-05 21:02 · Yahoo
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
2026-11-02 21:02 · Yahoo
Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On Sales
2026-10-29 08:24 · Yahoo
Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?
2026-10-13 09:11 · Yahoo
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
2026-09-14 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.